» Articles » PMID: 24386160

How Much Demand for New HIV Prevention Technologies Can We Really Expect? Results from a Discrete Choice Experiment in South Africa

Overview
Journal PLoS One
Date 2014 Jan 4
PMID 24386160
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: For the first time in the history of HIV, new bio-medical interventions have been shown to be effective in preventing HIV transmission. For these new HIV prevention technologies (NPTs) to have an impact on the epidemic, they must be widely used. This study uses a discrete choice experiment (DCE) to: understand the relative strength of women's preferences for product characteristics, understand the implications for substitution away from male condoms, and inform realistic modelling of their potential impact and cost-effectiveness.

Methods: A DCE was conducted among 1017 women in urban South Africa. Women were presented with choices between potential women's NPTs (microbicides, diaphragm, female condom) and 'what I did last time' (use or not use a condom) with different HIV and pregnancy prevention effectiveness' and prices. Choice probabilities are estimated using the nested logit model and used to predict uptake.

Results: In this high HIV prevalence setting, HIV prevention effectiveness is the main driver of uptake followed by pregnancy prevention effectiveness. For example a microbicide with poor effectiveness would have niche appeal at just 11% predicted uptake, while a highly effective microbicide (95% effective against HIV and pregnancy) would have far wider appeal (56% predicted uptake). Though women who reported not using condoms were more likely to choose the NPTs, at current very high rates of male condom use in South Africa (60%), about half of microbicide uptake is projected to be among those currently not using condoms.

Conclusions: Women are very interested in NPTs, especially if highly effective in preventing HIV and pregnancy. Women in greatest need were also most likely to switch to the new products. Where products are not yet available for distribution, proxy data, such as that generated by DCEs, can bring realism to overly optimistic uptake scenarios found in many current impact models.

Citing Articles

An Overview of Data Collection in Health Preference Research.

Ozdemir S, Quaife M, Mohamed A, Norman R Patient. 2024; .

PMID: 38662323 DOI: 10.1007/s40271-024-00695-6.


Uptake of a patient-centred dynamic choice model for HIV prevention in rural Kenya and Uganda: SEARCH SAPPHIRE study.

Kabami J, Kakande E, Chamie G, Balzer L, Petersen M, Camlin C J Int AIDS Soc. 2023; 26 Suppl 1:e26121.

PMID: 37408473 PMC: 10323314. DOI: 10.1002/jia2.26121.


Synthesis of end-user research to inform future multipurpose prevention technologies in sub-Saharan Africa: a scoping review.

Bhushan N, Ridgeway K, Luecke E, Palanee-Phillips T, Montgomery E, Minnis A Front Reprod Health. 2023; 5:1156864.

PMID: 37325244 PMC: 10264572. DOI: 10.3389/frph.2023.1156864.


Optimizing the pipeline of multipurpose prevention technologies: opportunities across women's reproductive lifespans.

Bershteyn A, Resar D, Kim H, Platais I, Mullick S Front Reprod Health. 2023; 5:1169110.

PMID: 37325241 PMC: 10266103. DOI: 10.3389/frph.2023.1169110.


Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis.

Milali M, Resar D, Kaftan D, Campbell J, Olowu A, Edwards D Front Reprod Health. 2023; 5:1144217.

PMID: 37266447 PMC: 10230827. DOI: 10.3389/frph.2023.1144217.


References
1.
McCormack S, Ramjee G, Kamali A, Rees H, Crook A, Gafos M . PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010; 376(9749):1329-37. PMC: 2956883. DOI: 10.1016/S0140-6736(10)61086-0. View

2.
Lee S, Newman P, Comulada W, Cunningham W, Duan N . Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences. Int J STD AIDS. 2012; 23(4):235-41. PMC: 3372064. DOI: 10.1258/ijsa.2011.011189. View

3.
Thurman A, Clark M, Doncel G . Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol. 2011; 2011:1-10. PMC: 3152961. DOI: 10.1155/2011/429403. View

4.
Cameron M, Newman P, Roungprakhon S, Scarpa R . The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine. 2013; 31(36):3712-7. DOI: 10.1016/j.vaccine.2013.05.089. View

5.
Hallett T, Baeten J, Heffron R, Barnabas R, de Bruyn G, Cremin I . Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011; 8(11):e1001123. PMC: 3217021. DOI: 10.1371/journal.pmed.1001123. View